China GMP Certification Lincomycin HCl/Lincomycin Powder Antibiotic Injection Manufacturing CAS: 859-18-7, Find details about China Lincomycin, Pharmaceutical from GMP Certification Lincomycin HCl/Lincomycin Powder Antibiotic Injection Manufacturing CAS: 859-18-7
Lincomycin HCl Synonyms: Lincomycin Hydrochloride CAS: 859-18-7 EINECS 212-726-7 Assay: 82.5~95.5% Standard: EP7.0/BP/USP Packing: 20Bou/cardboard drum MF: C18H35ClN2O6S MW: 443 Character: White crystalline powder. MP 156-158° C, pH3.5~5.5, Optical rotation +135~+150° . Solubility: H2O: 50 mg/mL, clear, colorless. Usage: An antibiotic produced by Streptomyces lincolnensis. Lincomycin is a lincosamide antibiotic that forms cross-links within the peptidyl transferase loop region of the 23S rRNA. Inhibits bacterial protein synthesis. Antibacterial. Lincomycin (hereinafter referred to as LCM) biosynthesis, in addition to produce LCM, but under certain conditions, also produced the LCM B, C, D, K, S and other analogues, thus refining process more difficult and costly. LD50 acute toxicity test showed that mice injected 1000mg/kg, rat oral greater than 4000mg/kg, toxicity is low. Indications: Effect as erythromycin, do not have to do skin test, the product of Gram-positive bacteria and gram-negative bacteria is stronger for osteomyelitis, sepsis, respiratory and soft tissue infections. This product is very strong penetration of bone, is the medicine of choice for osteomyelitis. Applications: Lincomycin is a lincosamide antibiotic that comes from the actinomyces Streptomyces lincolnensis.A related compound, clindamycin, is derived from lincomycin by using thionyl chloride to replace the 7-hydroxy group with a chlorine atom with inversion of chirality. Although similar in structure, antibacterial spectrum, and mechanism of action to macrolides, lincomycin is also effective against other organisms including actinomycetes, mycoplasma, and some species of Plasmodium.Intramuscular administration of a single dose of 600 mg of Lincomycin produces average peak serum levels of 11.6 micrograms/ml at 60 minutes, and maintains therapeutic levels for 17 to 20 hours, for most susceptible gram-positive organisms. Urinary excretion after this dose ranges from 1.8 to 24.8 percent (mean: 17.3 percent). A two-hour intravenous infusion of 600 mg of Lincomycin achieves average peak serum levels of 15.9 micrograms/ml and yields therapeutic levels for 14 hours for most susceptible gram-positive organisms. Urinary excretion ranges from 4.9 to 30.3 percent (mean: 13.8 percent). The biological half-life after IM or IV administration is 5.4 ± 1.0 hours. The serum half-life of lincomycin may be prolonged in patients with severe impairment of renal function, compared to patients with normal renal function. In patients with abnormal hepatic function, serum half-life may be twofold longer than in patients with normal hepatic function. Hemodialysis and peritoneal dialysis are not effective in removing lincomycin from the serum. Tissue level studies indicate that bile is an important route of excretion. Significant levels have been demonstrated in the majority of body tissues. Although lincomycin appears to diffuse in the cerebrospinal fluid (CSF), levels of lincomycin in the CSF appear inadequate for the treatment of meningitis. | |